BRAF and non-small cell lung carcinoma: The most frequently occurring oncogenic driver alterations in NSCLC patients involve the following genes: KRAS (Kirsten rat sarcoma virus), EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), ROS1 (ROS proto-oncogene 1), BRAF (proto-oncogene B-Raf), MET (mesenchymal-epithelial transition factor), RET (RET proto-oncogene), NTRK 1-3 (neurotrophic tyrosine kinase type 1-3) and HER2 (human epidermal growth factor receptor 2) [2].